DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy

This study evaluates whether radiotherapy can safely be omitted in breast cancer patients with T1-2N0 tumors who achieve a pathologic complete response after neoadjuvant systemic therapy and breast-conserving surgery

Trial Details

NCT ID
NCT05416164
Phase
NA
Sponsor
The Netherlands Cancer Institute
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Omission of radiotherapy
Locations (sample)
  • Amsterdam, North Holland, Netherlands|52.37403,4.88969

Key Eligibility Criteria

  • Women, aged ≥ 18 years
  • Invasive HR positive/Her2 negative, Her2+ (ER/PR +/-) or TN breast cancer
  • Concurrent DCIS in pre-NST biopsy is allowed if there is no suspicion of extensive component i.e. absence of non-mass enhancement on pre-NST MRI, c…
  • Primary tumour (T) clinical stage cT1-2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →